Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS

被引:14
作者
Paszat, Lawrence [1 ,2 ,3 ]
Sutradhar, Rinku [1 ,2 ]
Zhou, Limei [2 ]
Nofech-Mozes, Sharon [1 ,3 ]
Rakovitch, Eileen [1 ,2 ,3 ]
机构
[1] Univ Toronto, T2-156 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada
[2] Inst Clin Evaluat Sci, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
关键词
Ductal carcinoma in situ; Local recurrence; Multigene expression assay; Prediction model; Radiotherapy; BREAST-TUMOR RECURRENCES; RADIOTHERAPY; RISK; CANCER; SURGERY; WOMEN; OVERDIAGNOSIS; OVERTREATMENT; INDIVIDUALS; MORTALITY;
D O I
10.1016/j.clbc.2018.07.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinical care for women who have undergone breast-conserving surgery for ductal carcinoma-in-situ (DCIS) is controversial. Accurate prediction of the risks of recurrence would help inform decision making. Predictive models including the DCIS score multigene expression assay were developed using a complete case series of 1102 women; results indicate that such a model allows computation of more accurate risk of recurrence. Introduction: Individual prediction of local recurrence (LR) risk after breast-conserving surgery (BCS) for ductal carcinoma-in-situ (DCIS) is needed to identify women at low risk, for whom radiotherapy may be omitted. Patients and Methods: Three predictive models of LR-clinicopathologic factors (CPF) alone; CPF + estrogen receptor (ER) + human epidermal growth factor receptor 2 (HER2); and CPF + DCIS score (DS)-were developed among 1102 cases of DCIS in patients with complete covariate and outcome data. Categorizations of discrete variables and transformations of continuous variables were examined in Cox models; 2-way interactions and interactions with time were assessed. Internal validation was performed by bootstrapping. Individual predicted 10-year LR risks were computed from covariate values, estimated regression parameters, and estimated baseline survival function. Accuracy was assessed by c statistics and calibration plots. Results: The strongest prediction model incorporated CPF + DS. The c statistics for CPF + DS, CPF + ER + HER2, or CPF-alone models were 0.7025, 0.6879, and 0.6825, respectively. The CPF + DS model was better calibrated at predicting low (<= 10%) individual 10-year LR risks after BCS alone than those incorporating CPF + ER + HER2 or CPF alone, evidenced by c statistics and plots of observed by predicted risks. Among women aged >= 50 with no adverse CPF, the CPF + DS model identified the greatest proportion of women (62.3%) with predicted individual 10-year LR 10% <= without radiotherapy compared to the CPF + ER + HER2 (50.9%) or CPF alone (46.5%) models. Conclusion: Individual prediction of LR incorporating DS is more accurate and identifies a higher proportion of women with low predicted risk of LR after BCS alone, for whom radiotherapy may be omitted. (C) 2018 The Authors. Published by Elsevier Inc.
引用
收藏
页码:35 / 46
页数:12
相关论文
共 18 条
  • [1] [Anonymous], COCHRANE DATABASE SY
  • [2] Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
    Cuzick, Jack
    Sestak, Ivana
    Pinder, Sarah E.
    Ellis, Ian O.
    Forsyth, Sharon
    Bundred, Nigel J.
    Forbes, John F.
    Bishop, Hugh
    Fentiman, Ian S.
    George, William D.
    [J]. LANCET ONCOLOGY, 2011, 12 (01) : 21 - 29
  • [3] Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial
    Donker, Mila
    Litiere, Saskia
    Werutsky, Gustavo
    Julien, Jean-Pierre
    Fentiman, Ian S.
    Agresti, Roberto
    Rouanet, Philippe
    de lara, Christine Tunon
    Bartelink, Harry
    Duez, Nicole
    Rutgers, Emiel J. T.
    Bijker, Nina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4054 - 4059
  • [4] Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program
    Ernster, VL
    Barclay, J
    Kerlikowske, K
    Wilkie, H
    Ballard-Barbash, R
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) : 953 - 958
  • [5] Incidence of and treatment for ductal carcinoma in situ of the breast
    Ernster, VL
    Barclay, J
    Kerlikowske, K
    Grady, D
    Henderson, IC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (12): : 913 - 918
  • [6] Trends in the treatment of ductal carcinoma in situ of the breast
    Gotzsche, PC
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (16) : 1257 - 1257
  • [7] Precision surgery and avoiding over-treatment
    Hosseini, A.
    Khoury, A. L.
    Esserman, L. J.
    [J]. EJSO, 2017, 43 (05): : 938 - 943
  • [8] Overdiagnosis and overtreatment of breast cancer -: Progression of ductal carcinoma in situ:: the pathological perspective
    Jones, JL
    [J]. BREAST CANCER RESEARCH, 2006, 8 (02)
  • [9] Overdiagnosis and overtreatment of breast cancer -: Rates of ductal carcinoma in situ:: a US perspective
    Kumar, AS
    Bhatia, V
    Henderson, IC
    [J]. BREAST CANCER RESEARCH, 2005, 7 (06) : 271 - 275
  • [10] RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation
    McCormick, Beryl
    Winter, Kathryn
    Hudis, Clifford
    Kuerer, Henry Mark
    Rakovitch, Eileen
    Smith, Barbara L.
    Sneige, Nour
    Moughan, Jennifer
    Shah, Amit
    Germain, Isabelle
    Hartford, Alan C.
    Rashtian, Afshin
    Walker, Eleanor M.
    Yuen, Albert
    Strom, Eric A.
    Wilcox, Jeannette L.
    Vallow, Laura A.
    Small, William, Jr.
    Pu, Anthony T.
    Kerlin, Kevin
    White, Julia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07) : 709 - 715